Patents by Inventor Judith Dierlamm

Judith Dierlamm has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Molecular characterization of chromosome translocation t(11;18)(q21;q21) and its correlation to carcinogenesis
    Patent number: 7807809
    Abstract: Methods for determining whether a tissue sample or an analogue and/or derivative thereof comprises a cell with a chromosome (11:18) translocation associated with malignancies such as mucosa-associated lymphoid tissue (MALT) lymphomas. The invention further provides insight into a novel mechanism of transformation of primary cells. The mechanism involves expression of a fusion proteinaceous molecule comprising at least apoptosis inhibitor 2 (API2) or a functional part, derivative and/or analogue thereof fused to at least one other proteinaceous molecule. The invention also provides a novel nucleic acid sequence and proteinaceous molecule expressed from the sequence termed “MALT-lymphoma associated Translocation (MLT) protein.
    Type: Grant
    Filed: January 28, 2003
    Date of Patent: October 5, 2010
    Assignee: Vlaams Interuniversitair Instituut voor Biotechnologie VZW
    Inventors: Judith Dierlamm, Mathijs Baens, Peter Marijnen
  • Molecular characterization of chromosome translocation t(11;18)(q21;q21) and its correlation to carcinogenesis
    Patent number: 6689875
    Abstract: Methods for determining whether a tissue sample or an analogue and/or derivative thereof comprises a cell with a chromosome {11:18} translocation associated with malignancies such as mucosa-associated lymphoid tissue (MALT) lymphoma's. The invention further provides insight into a novel mechanism of transformation of primary cells. The mechanism involving expression of a fusion proteinaceous molecule comprising at least apoptosis inhibitor 2 (API2) or a functional part, derivative and/or analogue thereof fused to at least one other proteinaceous molecule. The invention also provides a novel nucleic acid sequence and proteinaceous molecule expressed from the sequence termed MALT-lymphoma associated Translocation (MLT) protein.
    Type: Grant
    Filed: May 26, 2000
    Date of Patent: February 10, 2004
    Assignee: Vlaams Interuniversitair Instituut voor Biotechnologie vzw
    Inventors: Judith Dierlamm, Mathijs Baens, Peter Marijnen
  • Molecular characterization of chromosome translocation t(11;18)(q21;q21) and its correlation to carcinogenesis
    Publication number: 20030176682
    Abstract: Methods for determining whether a tissue sample or an analogue and/or derivative thereof comprises a cell with a chromosome (11:18) translocation associated with malignancies such as mucosa-associated lymphoid tissue (MALT) lymphomas. The invention further provides insight into a novel mechanism of transformation of primary cells. The mechanism involves expression of a fusion proteinaceous molecule comprising at least apoptosis inhibitor 2 (API2) or a functional part, derivative and/or analogue thereof fused to at least One other proteinaceous molecule. The invention also provides a novel nucleic acid sequence and proteinaceous molecule expressed from the sequence termed “MALT-lymphoma associated Translocation (MLT) protein.
    Type: Application
    Filed: January 28, 2003
    Publication date: September 18, 2003
    Inventors: Judith Dierlamm, Mathijs Baens, Peter Marijnen